The Use of F-FDG PET/CT in Patients with Recurrent Differentiated Thyroid Cancer

Overview

Journal Mol Imaging Radionucl Ther

Date 2021 Oct 18

PMID 34658228

Authors

Ozgul Ekmekcioglu

Affiliations

Soon will be listed here.

Abstract

Objectives: Fluorine-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) is used to monitor the recurrence in thyroid cancer patients when there is suspicion of metastases. De-differentiated lesions become F-FDG avid with a more aggressive clinical course. The aim of this study was to investigate the use of F-FDG PET/CT in differentiated thyroid cancer.

Methods: Forty-six patients, either with a negative radioiodine scan or clinical progression and suspicions for metastases with differentiated thyroid cancer that were referred to our department for F-FDG PET/CT scan and evaluated retrospectively. PET/CT findings were correlated with clinical and histopathological findings, serum thyroglobulin (Tg), and anti-Tg levels.

Results: Twenty-six patients (56.2%) were positive for recurrence in F-FDG PET/CT images. Positive F-FDG PET/CT findings were significantly correlated with the disease stage and Tg levels. Maximum standardized uptake value did not correlate with other findings or patients' profiles. The cut-off value for Tg was at 52.5 ng/mL having 73.08% sensitivity, 75% specificity, 79.17% positive predictive value, and 68.18% negative predictive value for F-FDG PET/CT imaging.

Conclusion: F-FDG PET/CT is useful for detecting recurrence in differentiated thyroid cancer. Increased Tg levels and stage of the disease were significantly correlated with F-FDG positivity. F-FDG positivity may also provide information about the de-differentiation process that may support the treatment plan.

References

Jung J, Kim C, Son S, Kim D, Jeong S, Lee S . Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma. PLoS One. 2015; 10(12):e0144152. PMC: 4670197. DOI: 10.1371/journal.pone.0144152. View

Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S . F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009; 34(11):756-61. DOI: 10.1097/RLU.0b013e3181b7d95c. View

Kang J, Jung D, Pak K, Kim I, Kim H, Cho J . Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Head Neck. 2017; 40(1):94-102. DOI: 10.1002/hed.24967. View

Larg M, Barbus E, Gabora K, Pestean C, Cheptea M, Piciu D . 18F-FDG PET/CT IN DIFFERENTIATED THYROID CARCINOMA. Acta Endocrinol (Buchar). 2019; 15(2):203-208. PMC: 6711650. DOI: 10.4183/aeb.2019.203. View

Shammas A, Degirmenci B, Mountz J, McCook B, Branstetter B, Bencherif B . 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007; 48(2):221-6. View

Mazzaferri E, Jhiang S . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418-28. DOI: 10.1016/0002-9343(94)90321-2. View

Schluter B, Bohuslavizki K, Beyer W, Plotkin M, Buchert R, Clausen M . Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001; 42(1):71-6. View

Cooray S, Topliss D . The management of metastatic radioiodine-refractory differentiated thyroid cancer requires an integrated approach including both directed and systemic therapies. Endocrinol Diabetes Metab Case Rep. 2017; 2017. PMC: 5404474. DOI: 10.1530/EDM-16-0089. View

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

10.

Ha L, Iravani A, Nhung N, Hanh N, Hutomo F, Son M . Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma. Cancer Imaging. 2021; 21(1):8. PMC: 7792294. DOI: 10.1186/s40644-020-00378-z. View

11.

Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E . Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?. Q J Nucl Med Mol Imaging. 2011; 55(1):57-65. View

12.

Wang W, Macapinlac H, Larson S, Yeh S, Akhurst T, Finn R . [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999; 84(7):2291-302. DOI: 10.1210/jcem.84.7.5827. View

13.

Gild M, Topliss D, Learoyd D, Parnis F, Tie J, Hughes B . Clinical guidance for radioiodine refractory differentiated thyroid cancer. Clin Endocrinol (Oxf). 2017; 88(4):529-537. DOI: 10.1111/cen.13508. View

14.

Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H . Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2005; 91(2):498-505. DOI: 10.1210/jc.2005-1534. View

15.

Chong A, Ha J, Han Y, Kong E, Choi Y, Hong K . Preoperative Lymph Node Staging by FDG PET/CT With Contrast Enhancement for Thyroid Cancer: A Multicenter Study and Comparison With Neck CT. Clin Exp Otorhinolaryngol. 2016; 10(1):121-128. PMC: 5327587. DOI: 10.21053/ceo.2015.01424. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

17.

Cho S, Kwon S, Kim J, Cho D, Na M, Kang S . Risk factors of malignant fluorodeoxyglucose-avid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy. Medicine (Baltimore). 2019; 98(16):e14858. PMC: 6494284. DOI: 10.1097/MD.0000000000014858. View

18.

Grabellus F, Nagarajah J, Bockisch A, Schmid K, Sheu S . Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012; 37(2):121-7. DOI: 10.1097/RLU.0b013e3182393599. View

19.

Sherman S . Thyroid carcinoma. Lancet. 2003; 361(9356):501-11. DOI: 10.1016/s0140-6736(03)12488-9. View

20.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View